MET and cancer: Furthermore, the establishment of prognostically relevant PDL1-positive or MET-positive CTC assays would be a promising strategy for monitoring relapse and disease progression and providing therapeutic strategies to treat cancer patients, ultimately achieving patient-specific medication through companion diagnostics.